The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1432-0851

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial ; day:17 ; month:1 ; year:2019 ; pages:1-13
Cancer immunology immunotherapy ; (17.1.2019), 1-13

Creator: Huijts, Charlotte M.
Lougheed, Sinéad M.
Bodalal, Zuhir
van Herpen, Carla M.
Hamberg, Paul
Tascilar, Metin
Haanen, John B.
Verheul, Henk M.
de Gruijl, Tanja D.
van der Vliet, Hans J.

Contributor: SpringerLink (Online service)

DOI: 10.1007/s00262-018-2288-8

URN: urn:nbn:de:101:1-2019021818500200185744

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 11:03 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Huijts, Charlotte M.
Lougheed, Sinéad M.
Bodalal, Zuhir
van Herpen, Carla M.
Hamberg, Paul
Tascilar, Metin
Haanen, John B.
Verheul, Henk M.
de Gruijl, Tanja D.
van der Vliet, Hans J.
SpringerLink (Online service)

Other Objects (12)

Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma

Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer

$Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma$

Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma

Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus

Cancer stem cell subsets and their relationships

mTOR inhibitor everolimus reduces invasiveness of melanoma cells

mTOR inhibitor Everolimus-induced apoptosis in melanoma cells

Single-cell gene profiling analysis of human regulatory T cell subsets

Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma

Hochschulschrift

Immunomodulation of antigen-specific CD8+ T-cells by everolimus and mesenchymal stem cells

Combined low-dose everolimus and low-dose tacrolimus after Alemtuzumab induction therapy: a randomized prospective trial in lung transplantation

DOCK8 gene mutation alters cell subsets, BCR signaling, and cell metabolism in B cells

Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma

Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer

$Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma$

Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma

Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus

Cancer stem cell subsets and their relationships

mTOR inhibitor everolimus reduces invasiveness of melanoma cells

mTOR inhibitor Everolimus-induced apoptosis in melanoma cells

Single-cell gene profiling analysis of human regulatory T cell subsets

Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma

Hochschulschrift

Immunomodulation of antigen-specific CD8+ T-cells by everolimus and mesenchymal stem cells

Combined low-dose everolimus and low-dose tacrolimus after Alemtuzumab induction therapy: a randomized prospective trial in lung transplantation

DOCK8 gene mutation alters cell subsets, BCR signaling, and cell metabolism in B cells

Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma

Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer

$Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma$

Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma

Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus

Cancer stem cell subsets and their relationships

mTOR inhibitor everolimus reduces invasiveness of melanoma cells

mTOR inhibitor Everolimus-induced apoptosis in melanoma cells

Single-cell gene profiling analysis of human regulatory T cell subsets

Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma

Hochschulschrift

Immunomodulation of antigen-specific CD8+ T-cells by everolimus and mesenchymal stem cells

Combined low-dose everolimus and low-dose tacrolimus after Alemtuzumab induction therapy: a randomized prospective trial in lung transplantation

DOCK8 gene mutation alters cell subsets, BCR signaling, and cell metabolism in B cells

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma

Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer

Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma

Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus

Cancer stem cell subsets and their relationships

mTOR inhibitor everolimus reduces invasiveness of melanoma cells

mTOR inhibitor Everolimus-induced apoptosis in melanoma cells

Single-cell gene profiling analysis of human regulatory T cell subsets

Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma

Immunomodulation of antigen-specific CD8+ T-cells by everolimus and mesenchymal stem cells

Combined low-dose everolimus and low-dose tacrolimus after Alemtuzumab induction therapy: a randomized prospective trial in lung transplantation

DOCK8 gene mutation alters cell subsets, BCR signaling, and cell metabolism in B cells

Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma

Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer

Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma

Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus

Cancer stem cell subsets and their relationships

mTOR inhibitor everolimus reduces invasiveness of melanoma cells

mTOR inhibitor Everolimus-induced apoptosis in melanoma cells

Single-cell gene profiling analysis of human regulatory T cell subsets

Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma

Immunomodulation of antigen-specific CD8+ T-cells by everolimus and mesenchymal stem cells

Combined low-dose everolimus and low-dose tacrolimus after Alemtuzumab induction therapy: a randomized prospective trial in lung transplantation

DOCK8 gene mutation alters cell subsets, BCR signaling, and cell metabolism in B cells

Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma

Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer

Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma

Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus

Cancer stem cell subsets and their relationships

mTOR inhibitor everolimus reduces invasiveness of melanoma cells

mTOR inhibitor Everolimus-induced apoptosis in melanoma cells

Single-cell gene profiling analysis of human regulatory T cell subsets

Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma

Immunomodulation of antigen-specific CD8+ T-cells by everolimus and mesenchymal stem cells

Combined low-dose everolimus and low-dose tacrolimus after Alemtuzumab induction therapy: a randomized prospective trial in lung transplantation

DOCK8 gene mutation alters cell subsets, BCR signaling, and cell metabolism in B cells

Related objects

Reset password